Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells 

 

 

ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

July 12, 2012 - (ACT) - "Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt’s Macular Dystrophy (SMD). The surgery was performed on Wednesday, July 11 at Wills Eye Institute in Philadelphia, by a surgical team lead by Carl D. Regillo."  Read Full Article

 

Posted on 27-Jul-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: